Seattle Biotech InduPro Therapeutics Teams with Sanofi on Next-Gen Autoimmune Antibodies

Seattle-based InduPro Therapeutics has partnered with Sanofi to advance its preclinical bispecific PD-1 agonist antibodies for autoimmune diseases. Sanofi has made an equity investment and will support IND-enabling studies, gaining first access to any successful candidates. InduPro, which raised $85M in a Series A this year, also has early oncology programs and marks Sanofi as its first publicly disclosed pharma collaborator.